Skip to content
How It Works
Explore
Ask a Question Resources Pricing
Who It's For
Patients
Decode results, prep for appointments, weigh options.
Caregivers & advocates
Carry the research load for someone you love.
Providers & clinicians
Resources for patients in your practice.
Log In Sign Up
PubMed This is a summary of 18 peer-reviewed journal articles Updated
Endocrinology · Familial Partial Lipodystrophy Type 3

Pregnancy & Reproductive Health

At a Glance

Pregnancy with FPLD3 requires preconception planning and close care from an endocrinologist or lipid specialist, a maternal-fetal medicine team, and a dietitian because insulin resistance can sharply raise triglycerides and blood sugar, increasing risks such as pancreatitis and preeclampsia.

For women with Familial Partial Lipodystrophy Type 3 (FPLD3), reproductive health is often the first area where symptoms appear. Because the body cannot store fat properly, the resulting high insulin levels can disrupt the delicate hormonal balance required for regular cycles and healthy pregnancies [1][2].

The PCOS-like Connection

Many women with FPLD3 experience symptoms that look identical to Polycystic Ovary Syndrome (PCOS). Studies of specific cohorts have found that between 58% and 75% of women with FPLD3 experience PCOS-like features [3][4].

This overlap is driven by hyperinsulinemia (excessively high insulin in the blood). When your body resists insulin, it produces more to compensate. This extra insulin can signal the ovaries to produce too much testosterone, leading to [5]:

  • Hirsutism: Unwanted hair growth on the face or body [6].
  • Irregular Menses: Absent or infrequent periods, which can make it difficult to track ovulation [7].
  • Fertility Challenges: Difficulty conceiving due to irregular ovulation [6].

Pregnancy: A High-Risk Journey

Pregnancy is a metabolic stress test. Even in healthy pregnancies, the body naturally becomes more insulin resistant to ensure the baby gets enough energy. In FPLD3, this natural shift can push blood sugar and lipid levels into severe ranges [8][9].

The primary risks during an FPLD3 pregnancy include:

  • Severe Hypertriglyceridemia: Triglycerides can rise to extreme levels, which carries a high risk of acute pancreatitis [8][10].
  • Gestational Diabetes: Managing blood sugar becomes significantly more difficult, often requiring insulin [11][12].
  • Hypertension and Preeclampsia: Women with FPLD3 may have a higher risk of developing high blood pressure or preeclampsia during pregnancy [12][8].
  • Fetal Risks: Complications can include macrosomia (a very large baby), premature birth, or neonatal hypoglycemia (low blood sugar in the baby after birth), though these are not inevitable [12].

Preconception Planning and Management

Success in an FPLD3 pregnancy depends on early, intensive, and multidisciplinary care. Ideally, planning should begin before conception while using reliable contraception until a plan is established [12][13].

  • Multidisciplinary Team: Your care should involve an endocrinologist or lipid specialist, a Maternal-Fetal Medicine (MFM) specialist (high-risk OB), and a registered dietitian [8][13].
  • Medication Review: Statins are generally avoided in pregnancy, though some very high-risk patients may continue them based on individualized specialist decisions. Fibrates, omega-3 products, and certain diabetes drugs require trimester- and patient-specific decisions [8][14][15].
  • Insulin Therapy: Insulin is frequently used to manage blood sugar during pregnancy, and is sometimes used acutely for severe triglycerides [8][10].
  • Strict Dietary Management: You may be asked to follow a carefully supervised diet to prevent your triglycerides from reaching the pancreatitis threshold [16][9].
  • Emergency Options: If triglycerides become dangerously high and do not respond to diet or insulin, doctors may use therapeutic plasma exchange (plasmapheresis) to mechanically “wash” the fats out of your blood [17][18].

Common questions in this guide

Can FPLD3 cause irregular periods or fertility problems?
Yes. High insulin levels associated with FPLD3 can affect ovarian hormone signals and ovulation, causing irregular or absent periods, excess hair growth, and difficulty conceiving. Better insulin control may improve some symptoms, but fertility planning should be individualized with your healthcare team.
Why is pregnancy considered high risk with FPLD3?
Pregnancy naturally increases insulin resistance, and FPLD3 can make that change more pronounced. Blood sugar and triglycerides may rise sharply, increasing the risks of gestational diabetes, severe high triglycerides with pancreatitis, high blood pressure, and preeclampsia. Close monitoring can help the care team respond early.
Which specialists should be involved before and during an FPLD3 pregnancy?
Planning should begin before conception with an endocrinologist or lipid specialist, a maternal-fetal medicine specialist who manages high-risk pregnancies, and a registered dietitian. The team can review medications, set monitoring goals, and create a plan for blood sugar and triglyceride control.
How are high triglycerides managed during an FPLD3 pregnancy?
Management may include a carefully supervised diet, frequent laboratory monitoring, and insulin when needed for blood sugar or severe triglycerides. Medication choices, including fibrates and omega-3 products, depend on the trimester and individual risks. If triglycerides become dangerously high despite initial treatment, therapeutic plasma exchange may be considered in a suitably equipped hospital.
Do I need to change my FPLD3 medications before trying to conceive?
A medication review is important before conception, but do not stop or switch medicines without your clinician. Statins are generally avoided during pregnancy, while fibrates, omega-3 products, and some diabetes medicines require individualized decisions based on the medication, trimester, and maternal risk.
Can FPLD3 affect the baby during pregnancy?
It can increase the chance of a very large baby, premature birth, or low blood sugar in the newborn, especially when maternal blood sugar is difficult to control. These complications are not inevitable, and coordinated prenatal care can help monitor and manage risk.

Questions For You

Answer a question to get research tailored to you. Your answers are private.

Get notified when new evidence is published on PPARG-related familial partial lipodystrophy.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.Given that I have FPLD3, should we manage my pregnancy through a Maternal-Fetal Medicine (MFM) specialist?
  2. 2.What is my specific 'safe' triglyceride target for each trimester to minimize the risk of pancreatitis?
  3. 3.If my triglycerides spike dangerously, does this hospital have the capability to perform therapeutic plasma exchange?
  4. 4.Are my PCOS-like symptoms, like irregular periods, likely to resolve or improve with better insulin management?
  5. 5.Which of my current medications (like fibrates or statins) need to be safely stopped or switched before I try to conceive?

References

References (18)
  1. 1

    Familial Partial Lipodystrophy (FPLD): Recent Insights.

    Bagias C, Xiarchou A, Bargiota A, Tigas S

    Diabetes, metabolic syndrome and obesity : targets and therapy 2020; (13()):1531-1544 doi:10.2147/DMSO.S206053.

    PMID: 32440182
  2. 2

    Gene-gene and gene-environment interactions in lipodystrophy: Lessons learned from natural PPARγ mutants.

    Broekema MF, Savage DB, Monajemi H, Kalkhoven E

    Biochimica et biophysica acta. Molecular and cell biology of lipids 2019; (1864(5)):715-732 doi:10.1016/j.bbalip.2019.02.002.

    PMID: 30742913
  3. 3

    Familial partial lipodystrophy resulting from loss-of-function PPARγ pathogenic variants: phenotypic, clinical, and genetic features.

    Soares RMV, da Silva MA, Campos JTAM, Lima JG

    Frontiers in endocrinology 2024; (15()):1394102 doi:10.3389/fendo.2024.1394102.

    PMID: 39398333
  4. 4

    Perinatal, metabolic, and reproductive features in PPARG-related lipodystrophy.

    Gosseaume C, Fournier T, Jéru I, et al.

    European journal of endocrinology 2023; (188(3)) doi:10.1093/ejendo/lvad023.

    PMID: 36806620
  5. 5

    Effect of insulin on AKR1C3 expression in female adipose tissue: in-vivo and in-vitro study of adipose androgen generation in polycystic ovary syndrome.

    O'Reilly M, Gathercole L, Capper F, et al.

    Lancet (London, England) 2015; (385 Suppl 1()):S16.

    PMID: 26312838
  6. 6

    Familial Partial Lipodystrophy-Literature Review and Report of a Novel Variant in PPARG Expanding the Spectrum of Disease-Causing Alterations in FPLD3.

    Rutkowska L, Salachna D, Lewandowski K, et al.

    Diagnostics (Basel, Switzerland) 2022; (12(5)) doi:10.3390/diagnostics12051122.

    PMID: 35626278
  7. 7

    Familial partial lipodystrophy linked to a novel peroxisome proliferator activator receptor -γ (PPARG) mutation, H449L: a comparison of people with this mutation and those with classic codon 482 Lamin A/C (LMNA) mutations.

    Demir T, Onay H, Savage DB, et al.

    Diabetic medicine : a journal of the British Diabetic Association 2016; (33(10)):1445-50 doi:10.1111/dme.13061.

    PMID: 26756202
  8. 8

    First diagnosis of familial partial lipodystrophy syndrome type 3 during pregnancy associated with a novel heterozygous PPARG variant and a concurrent ABCC8 variant: a case report.

    Holstein A, Jabri I, Linck JA, et al.

    Frontiers in endocrinology 2026; (17()):1855679 doi:10.3389/fendo.2026.1855679.

    PMID: 42440509
  9. 9

    Navigating hypertriglyceridemia in pregnancy: current evidence and clinical strategies.

    Chamerski S, Wartecka-Zielińska K, Pomorski F, et al.

    Frontiers in endocrinology 2026; (17()):1761761 doi:10.3389/fendo.2026.1761761.

    PMID: 42181215
  10. 10

    Efficacy of insulin in treating severe hypertriglyceridaemia in the third trimester of pregnancy.

    Zhou D, Sun G, Hu J, Gan Q

    Frontiers in medicine 2022; (9()):977620 doi:10.3389/fmed.2022.977620.

    PMID: 36405614
  11. 11

    Familial partial lipodystrophy, Dunnigan variety - challenges for patient care during pregnancy: a case report.

    Belo SP, Magalhães ÂC, Freitas P, Carvalho DM

    BMC research notes 2015; (8()):140 doi:10.1186/s13104-015-1065-4.

    PMID: 25885670
  12. 12

    Gestational and neonatal outcomes of women with partial Dunnigan lipodystrophy.

    Valerio CM, Muniz RBG, Viola LF, et al.

    Frontiers in endocrinology 2024; (15()):1359025 doi:10.3389/fendo.2024.1359025.

    PMID: 38633761
  13. 13

    Dunnigan lipodystrophy syndrome: French National Diagnosis and Care Protocol (PNDS; Protocole National de Diagnostic et de Soins).

    Mosbah H, Donadille B, Vatier C, et al.

    Orphanet journal of rare diseases 2022; (17(Suppl 1)):170 doi:10.1186/s13023-022-02308-7.

    PMID: 35440056
  14. 14

    Familial chylomicronemia syndrome caused by 2 genetic variants in the APOA5 gene: Severe hypertriglyceridemia that complicates pregnancy.

    Gutiérrez J, Castaño P, Fariña G, et al.

    Journal of clinical lipidology 2025; (19(3)):701-706 doi:10.1016/j.jacl.2024.12.020.

    PMID: 40023744
  15. 15

    Pregnancy Outcomes Following Maternal Fenofibrate Exposure.

    Uysal N, Colak O, Gultekin O, Akici A

    Congenital anomalies 2026; (66(1)):e70079 doi:10.1002/cga.70079.

    PMID: 42723444
  16. 16

    A Comprehensive Update on the Chylomicronemia Syndrome.

    Goldberg RB, Chait A

    Frontiers in endocrinology 2020; (11()):593931 doi:10.3389/fendo.2020.593931.

    PMID: 33193106
  17. 17

    Therapeutic plasma exchange for the management of severe gestational hypertriglyceridaemic pancreatitis due to lipoprotein lipase mutation.

    Kim AS, Hakeem R, Abdullah A, et al.

    Endocrinology, diabetes & metabolism case reports 2020; (2020()).

    PMID: 32168469
  18. 18

    The role of apheresis and insulin therapy in hypertriglyceridemic acute pancreatitis-a concise review.

    Gubensek J

    BMC gastroenterology 2023; (23(1)):341 doi:10.1186/s12876-023-02957-3.

    PMID: 37789261

This page is for informational purposes only and does not constitute medical advice about FPLD3 pregnancy or fertility. Medication changes and pregnancy planning should be directed by your endocrinologist, lipid specialist, and maternal-fetal medicine team.